American journal of cancer research最新文献

{"title":"Erratum: GALNT6 suppresses progression of colorectal cancer.","authors":"Jing Duan, Lin Chen, Huabin Gao, Tiantian Zhen, Hui Li, Jiangtao Liang, Fenfen Zhang, Huijuan Shi, Anjia Han","doi":"10.62347/PZNV3765","DOIUrl":"https://doi.org/10.62347/PZNV3765","url":null,"abstract":"<p><p>[This corrects the article on p. 2419 in vol. 8, PMID: 30662801.].</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4196-4197"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FAM49B suppresses ovarian cancer cell growth through regulating MAPK signaling.","authors":"Chen Yue, Dong Zhou, Yuzhao Zhou, Qidong Feng, Kun Fang, Songshu Meng, Weiting Yu, Sha Du, Dachuan Shen, Yifei Wang","doi":"10.62347/LVDV6967","DOIUrl":"10.62347/LVDV6967","url":null,"abstract":"<p><p>Recently, the family with sequence similarity 49 member B (FAM49B, also called CYRI-B) has garnered attention as a new target in cancer development. FAM49B is upregulated in ovarian cancer tissues; however, its role and mechanism in ovarian cancer progression remain unknown. Herein, we demonstrated that FAM49B knockdown significantly increases ovarian cancer cell viability, EdU incorporation, and clonogenic growth. In contrast, the forced expression of FAM49B achieved opposite effects. Furthermore, an ovo model was used to assess the in vitro effects of FAM49B depletion or overexpression on the growth of ovarian cancer. In a xenograft model, we observed that FAM49B overexpression alleviated tumor formation. Transcriptomic analysis of FAM49B-depleted and control cells revealed that FAM49B silencing upregulated the MAPK pathway. Consistent with the transcriptomic analysis results, we noted that FAM49B knockdown enhanced EGFR activation and downstream MEK-ERK signaling; in contrast, FAM49B overexpression exhibited opposite trends. In addition, FAM49B played a role in EGF-induced sphere growth of ovarian cancer cells. Notably, treatment with the MEK inhibitor trametinib considerably impaired the increased cell growth by FAM49B knockdown in cell culture and ovo models. Collectively, our results suggest that FAM49B can suppress the growth of ovarian cancer cells by regulating the MAPK signaling pathway.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4150-4164"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145327939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative genomic analysis of left- and right-sided colon cancer using real-world data from the AACR project GENIE BPC dataset.","authors":"Younggwang Kim, Min Ki Kim, Sanghun Lee","doi":"10.62347/JOGM1897","DOIUrl":"10.62347/JOGM1897","url":null,"abstract":"<p><p>Left- and Right-sided colon cancers (LCC and RCC) are increasingly recognized as distinct clinicopathological and molecular subtypes with divergent prognoses and therapeutic responses. Leveraging a large, multi-institutional cohort from the AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC) (n = 750; LCC: 363 vs. RCC: 387), we conducted a comprehensive analysis of mutational profiles, tumor mutation burden (TMB), and survival outcomes. Our findings revealed a markedly higher TMB in RCC compared to LCC (6.65 ± 11.3 vs. 3.17 ± 4.35; adjusted <i>P</i> = 3.12×10^-32), suggesting greater genomic instability in RCC. After applying functional annotation filters (PolyPhen > 0.85, SIFT < 0.05), RCC tumors were significantly enriched for mutations in <i>BRAF</i> (23.1% vs. 6.7%), <i>KMT2D</i> (8.6% vs. 3.2%), and <i>SMAD4</i> (13.1% vs. 7.3%), while <i>TP53</i> mutations predominated in LCC (40.6% vs. 31.8%). Multivariate Cox regression analysis identified RCC as an independent predictor of poorer overall survival (OS) relative to LCC (HR: 1.30, 95% CI: 1.02-1.66, <i>P</i> = 0.033). Notably, <i>KRAS</i> mutations were associated with significantly worse OS in LCC (HR: 1.68, 95% CI: 1.06-2.70, <i>P</i> = 0.027), while <i>BRAF</i> mutations predicted adverse outcomes in RCC (HR: 1.58, 95% CI: 1.05-2.37, <i>P</i> = 0.028). These results underscore the prognostic value of tumor sidedness and specific genetic alterations in colon adenocarcinoma. Our study highlights the need for sidedness-specific molecular profiling to inform precision oncology strategies in colon cancer management.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4182-4194"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145327973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of chemotherapy with G-CSF versus plerixafor with G-CSF in autologous stem cell mobilization for lymphoma patients.","authors":"Jin Zhao, Xiaolian Wen, Li Ma, Xiaojing Guo, Liping Su","doi":"10.62347/XSXL9602","DOIUrl":"10.62347/XSXL9602","url":null,"abstract":"<p><strong>Aims: </strong>To compare the efficacy, safety, hematological recovery, immune reconstitution, infection rates, and quality of life (QoL) between two stem cell mobilization regimens - granulocyte colony-stimulating factor (G-CSF) plus chemotherapy versus G-CSF plus plerixafor - in patients with lymphoma undergoing autologous stem cell transplantation (ASCT).</p><p><strong>Methods: </strong>A retrospective cohort study was conducted in 174 lymphoma patients who underwent stem cell transplantation at Shanxi Province Cancer Hospital from 2010 to 2024. Patients were divided into two cohorts: G-CSF plus chemotherapy (n=129) and G-CSF plus plerixafor (n=45). Baseline demographics, CD34+ cell yield and collection efficiency, time to hematopoietic recovery, transfusion requirements, incidence of fever and infections, hematologic abnormalities, immune reconstitution, and patient-reported QoL at 6 months were collected from de-identified medical records and analyzed.</p><p><strong>Results: </strong>Baseline characteristics were comparable between groups. The G-CSF plus plerixafor group demonstrated significantly higher CD34+ cell counts at the first apheresis, higher total CD34+ cell yields, and a larger proportion of patients achieving ≥ 2 × 10⁶ and ≥ 5 × 10⁶ CD34+ cells/kg within 4 days compared with the G-CSF plus chemotherapy group. Hematological recovery (platelet and neutrophil engraftment) was faster in the plerixafor group. The plerixafor group also had shorter hospital stays, fewer febrile episodes during neutropenia, reduced antibiotic use, and higher lymphocyte counts at day 28 post-transplantion. The incidences of leukopenia, lymphopenia, anemia, and gastrointestinal adverse effects were lower in this group. Immune reconstitution, particularly CD4+ and CD8+ T cell recovery at 30 days, was improved post-transplant, and QoL scores at 6 months post-discharge were higher across physical, emotional, and social domains.</p><p><strong>Conclusion: </strong>Mobilization with G-CSF plus plerixafor is associated with higher CD34+ cell yields, faster hematologic and immune recovery, lower complication rates, and better QoL outcomes compared with G-CSF plus chemotherapy in lymphoma patients undergoing ASCT.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4165-4181"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531286/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Endoplasmic reticulum stress in non-small cell lung cancer.","authors":"Xiaodong Li, Fangning Hu, Tong Lu, Shuo Wu, Guanqiang Ma, Yani Lin, Hua Zhang","doi":"10.62347/YIFT7815","DOIUrl":"https://doi.org/10.62347/YIFT7815","url":null,"abstract":"<p><p>[This corrects the article on p. 1829 in vol. 15, PMID: 40371139.].</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4195"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deficiency of DAZ genes links testicular germ cell tumorigenesis and infertility: evidence from human embryonic stem cell germline differentiation.","authors":"Junqing Chen, Chuyu Li, Shuangshuang Qiu, Wenrui Zhu, Xi He, Dawei Gao, Zifeng Chen, Xingli Tong, Feiyang Diao","doi":"10.62347/NDPD8973","DOIUrl":"10.62347/NDPD8973","url":null,"abstract":"<p><p>Y-chromosome AZFc deficiency, which includes the DAZ gene family, is one of the most common genetic causes of severe male infertility. Epidemiological and molecular evidence suggest a developmental link between abnormalities in germ cell development and testicular germ cell tumor (TGCT), but whether and how DAZ deficiency is associated with TGCT susceptibility remains unclear. Using a specific human embryonic stem cell (hESC) model, we constructed and characterized a DAZ-deleted cell line (SKLRMe001-A) and compared its efficiency of induction into human primordial germ cell-like cells (hPGCLCs) with that of the H1 control line. We assessed intersections between embryonic-like networks and HMGA1-P53-MAPK/PI3K pathways to explore the potential connection between DAZ deficiency and TGCT susceptibility. DAZ deficiency significantly reduced hPGCLC induction efficiency and downregulated early lineage markers such as SOX17, BLIMP1, and TFAP2C, accompanied by S-phase shortening, cell cycle dysregulation, and increased apoptosis. RNA sequencing and enrichment analyses indicated sustained upregulation of HMGA1 and pointed to dysregulated homeostasis of P53 stress responses and PI3K/AKT and MAPK signaling axes. These findings are consistent with features of TGCT, including maintenance of embryonic-like programs, activation of proliferative signals, and heightened DNA damage responses. Therefore, we propose that lineage differentiation defects and mismatches between stress and survival signaling caused by DAZ deficiency may produce in vivo a population of \"undifferentiated and susceptible\" cells that increase the risk of TGCT, while also explaining the developmental basis of male infertility. Using a human in vitro model, this study links DAZ deficiency to both infertility and TGCT susceptibility and identifies HMGA1 as a central transcriptional-signaling hub. This finding provides molecular clues for risk stratification and early surveillance in populations with DAZ deficiency and suggests that interventions targeting HMGA1 and the PI3K/AKT and MAPK pathways may simultaneously improve germline differentiation and reduce potential tumor risk.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4067-4081"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145327964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating nivolumab with preceded gemcitabine and S-1 chemotherapy for patients of metastatic pancreatic cancer: a pilot study.","authors":"Shih-Hung Yang, Bang-Bin Chen, Jen-Chieh Lee, Yu-Ting Kuo, Sun-Hsin Kuo, Ann-Lii Cheng, Kun-Huei Yeh","doi":"10.62347/NJOX8790","DOIUrl":"10.62347/NJOX8790","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) rarely responds to immune checkpoint inhibitors. We conducted a pilot study to investigate chemotherapy followed by the addition of nivolumab in metastatic PDAC with limited tumor burden. A single cycle of gemcitabine (850 mg/m² on days 1 and 8) and S-1 (60-100 mg/day on days 1-12) was administered. Patients who had achieved control of carbohydrate antigen 19-9 (CA 19-9) (a decreased level of CA 19-9 or <10% increased level of CA 19-9 comparing to baseline) were provided adding-on nivolumab (3 mg/kg on days 1, 15, and 29) with the same doses of gemcitabine (on days 1, 8, 22, and 29) and S-1 (on days 1-12 and 22-33). The primary endpoint was response rate (RR). After enrolling seven patients, the study was terminated owing to slow recruitment. Five of the seven patients who completed one cycle of gemcitabine plus S-1 (GS) fulfilled the criteria for CA 19-9 and proceeded to receive nivolumab in addition to GS. One patient demonstrated a partial response, and the other four patients had stable disease (SD). The RR and disease control rate (DCR) for gemcitabine and S-1 plus nivolumab (GSN) were 20% and 100%, respectively. The median progression-free survival (PFS) was 6.3 (95% confidence interval [CI], 0-16.4) months. The median overall survival (OS) was 20.8 (95% CI, 16.4-25.2) months. Two patients who did not receive nivolumab continued the GS regimen; one SD and one progressive disease (PD) were observed with a PFS of 3.5 and 3.0 months, respectively. The most common adverse events (AEs) during the GS phase (n = 7) were grade 1-2 neutropenia (n = 5), skin rashes (n = 4), and fever (n = 3). During the nivolumab adding-on phase (n = 5), one grade 3 and one grade 4 neutropenia were observed. Grade 1-2 mucositis (n = 3) was the most common nonhematological AE. In conclusion, adding nivolumab to chemotherapy in patients who had achieved control of CA 19-9 in metastatic PDAC was feasible. (Registration at ClinicalTrials.gov: NCT04377048).</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4108-4120"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145327995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of red blood cells, D-dimer, and 13-(S)-HODE with cancer-related ischemic stroke: a case-control study.","authors":"Lingyun Xie, Kun Hao, Jian Shen, Cheng Huang","doi":"10.62347/RHLH9776","DOIUrl":"10.62347/RHLH9776","url":null,"abstract":"<p><p>This study aimed to investigate the clinical characteristics of CRIS and potential laboratory indicators. Acute ischemic stroke (AIS) patients were retrospectively enrolled and categorized into two groups: a cancer-related ischemic stroke (CRIS) group (n = 41) and a non-cancer ischemic stroke group (NC-IS) (n = 213). Baseline characteristics were balanced using 1:1 propensity score matching, adjusting for age, sex, and comorbidities, resulting in 41 patients per group. Serum levels of 13-(S)-hydroxyoctadecadienoic acid [13-(S)-HODE] and nine routine laboratory indicators were measured. Univariate and multivariate logistic regression identified CRIS-associated indicators. Independently associated indicators were evaluated using ROC curve analysis. Additionally, cancer patients without stroke (CNSP, n = 40) and healthy controls (NC, n = 41) were matched to compare routine indicators. Respiratory (34.1%) and digestive (29.3%) cancers were the most common in CRIS patients. Stroke occurred within six months of cancer diagnosis in 36.6% of patients, and 75.6% had multifocal cortical-subcortical infarctions. Multivariate regression confirmed that decreased red blood cells (RBCs) (OR = 0.444, 95% CI: 0.205-0.961), elevated D-dimer (OR = 2.41, 95% CI: 1.67-3.48), and decreased 13-(S)-HODE (OR = 3.20, 95% CI: 1.92-5.33) were independent risk factors for CRIS. The AUCs for the three indicators and the combined model were: RBC, 0.642; D-dimer, 0.739; 13-(S)-HODE, 0.722; combined model, 0.819 (95% CI: 0.729-0.908). CRIS patients had significantly higher D-dimer than CNSP patients (<i>P</i> = 0.001), and lower RBC, lower creatinine, and higher D-dimer than NCs (all <i>P</i> < 0.01). A combined model incorporating decreased RBC, elevated D-dimer, and decreased 13-(S)-HODE demonstrated a significant association with CRIS, showing potential for aiding the distinction of CRIS from NC-IS.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4054-4066"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145327975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary rehabilitation improves lung function and exercise tolerance in elderly non-surgical NSCLC patients.","authors":"Can Ao, Lu Zhan","doi":"10.62347/ZGQU3222","DOIUrl":"10.62347/ZGQU3222","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical efficacy and safety of pulmonary rehabilitation exercise training in improving lung function, exercise tolerance, cancer-related fatigue, and quality of life in elderly patients with non-surgical non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>A total of 186 elderly NSCLC patients who received non-surgical treatment at The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College from April 2023 to October 2024 were retrospectively enrolled. Among them, 95 received routine treatment (control group), and 91 received pulmonary rehabilitation training in addition to routine treatment (rehabilitation group). The intervention lasted 8 weeks. Evaluation indicators included lung function, exercise tolerance, respiratory function, cancer-related fatigue, quality of life, negative emotions, and sleep quality. Adverse reactions were also recorded.</p><p><strong>Results: </strong>By week 4, the social and emotional function in the EORTC QLQ-C30 showed no significant improvement, but by week 8, the rehabilitation group exhibited significantly better outcomes than the control group. Moreover, the rehabilitation group demonstrated significantly greater improvements in lung function, exercise tolerance, respiratory symptoms, cancer-related fatigue, and psychological status than the control group at week 8 (<i>P</i><0.05). In addition, the incidence of adverse reactions in the rehabilitation group was significantly lower (<i>P</i><0.05).</p><p><strong>Conclusion: </strong>Pulmonary rehabilitation training can effectively improve lung function and exercise capacity in elderly non-surgical NSCLC patients, alleviate fatigue and anxiety, enhance quality of life, and is safe for clinical application.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4029-4042"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise pre-conditioning prevents vascular toxicity caused by infusion of 5-fluorouracil in male rats.","authors":"Stephen T Hammond, Dryden R Baumfalk, Andrew G Horn, Britton C Scheuermann, Olivia N Kunkel, Carl J Ade, Bradley J Behnke","doi":"10.62347/UCJB2516","DOIUrl":"10.62347/UCJB2516","url":null,"abstract":"<p><p>5-fluorouracil (5-FU) is one of the most common chemotherapies used in cancer treatment yet is often associated with acute cardiotoxicity (e.g., angina, vasospasm). To date, countermeasures to prevent 5-FU cardiotoxicity are lacking. Therefore, we tested the hypothesis that short-term, moderate-intensity exercise completed before 5-FU administration would prevent 5-FU-induced alterations in vascular and cardiac function. Male Sprague-Dawley rats were randomized to sedentary control (SEDCON, n = 9), sedentary 5-FU (SED5FU, n = 10), exercise control (EXCON, n = 8) or exercise 5-FU (EX5FU, n = 8) groups. Rats remained sedentary or completed 4-days of treadmill running (20-25 min, 20 m/min, 5% grade) with the final bout ending ~90-min before treatment with a clinically relevant dose of 5-FU (50 mg/kg bolus + 265 mg/kg 2-hr infusion) or volume matched saline. Echocardiographic indices of left ventricular function and Doppler measurements of aortic pulse wave velocity (PWV) were completed at baseline (BL) and after the 2-hr (2-hr) infusion. 5-FU did not induce changes in left ventricular function. PWV increased from BL to 2-hr in SED5FU (BL: 396 ± 39 cm/s; 2-hr: 452 ± 54 cm/s; P = 0.002), but not SEDCON (BL: 417 ± 55 cm/s; 2-hr: 392 ± 64 cm/s; P = 0.35), EXCON (BL: 408 ± 35 cm/s; 2-hr: 410 ± 46 cm/s; P > 0.99), or EX5FU (BL: 398 ± 13 cm/s; 2-hr: 417± 23 cm/s; P = 0.67). Additionally, PWV at the 2-hr time point was significantly higher in SED5FU compared to SEDCON (P = 0.002). These findings suggest that moderate-intensity exercise preconditioning may protect against 5-FU-induced alterations in arterial PWV-potentially mitigating early signs of cardiotoxicity. Future studies are warranted to identify the mechanisms of 5-FU-induced cardiotoxicity and the feasibility and efficacy of pre-treatment exercise regimens in human patients.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 9","pages":"4092-4107"},"PeriodicalIF":2.9,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145327936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}